BVNRY

Healthcare Biotechnology

Bavarian Nordic A/S

$11.09
+0.01 +0.09% today

Price History

Not enough data

Key Stats

Market Cap
2.50B
Avg Volume
2,643
P/E (TTM)
10.98
EPS
$1.01
52W High
$13.00
52W Low
$8.67
Div. Yield
0.0%

Valuation

P/B Ratio
1.27
P/S Ratio
0.39
EV/EBITDA
0.17
EV/Revenue
0.05

Margins

Gross Margin 50.2%
Operating Margin 36.8%
Net Margin 24.3%
EBITDA Margin 28.1%

Growth & Returns

Revenue Growth (YoY)
23.2%
Earnings Growth (YoY)
169.7%
Earnings Growth (QoQ)
101.8%
Return on Equity
12.2%
Return on Assets
5.0%

Liquidity & Leverage

Current Ratio
6.53
Quick Ratio
3.83
Debt / Equity
0.01
Total Cash
2.36B
Total Debt
131.34M

About

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com